Completed
Saccharomyces Boulardii for Chronic Diarrhea in HIV-Infected Patients
What is being tested
Saccharomyces boulardii
Drug
Who is being recruted
Blood-Borne Infections+18
+ Urogenital Diseases
+ Genital Diseases
Over 18 Years
+10 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 2
Interventional
Summary
Principal SponsorBiocodex
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
This study focuses on treating HIV-related chronic diarrhea. It aims to evaluate the effectiveness of a non-harmful yeast called Saccharomyces boulardii in reducing diarrheal symptoms in HIV patients dealing with persistent diarrhea. The importance of this study lies in its potential to improve the quality of life for HIV patients, addressing a common and distressing symptom associated with the condition.
Principal SponsorBiocodex
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
100 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSigns and SymptomsSigns and Symptoms, DigestiveSlow Virus DiseasesPathological Conditions, Signs and SymptomsVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexDiarrheaHIV Infections
Criteria
8 inclusion criteria required to participate
Allowed concurrent medication: Antiviral medication for HIV infection
Allowed prior medication: Prior antiviral medication for HIV infection (if on such medication, must have received it for at least 2 weeks)
Allowed prior medication: Standard antimicrobial therapy for a documented positive gastrointestinal pathogen
Patients must have chronic diarrhea (for at least 1 month) that is either a manifestation or complication of documented HIV infection
Show More Criteria
2 exclusion criteria prevent from participating
Excluded concurrent medication: Gastrointestinal medications that cause diarrhea (e.g., magnesium-containing antacids, lactulose)
Excluded concurrent medication: Maintenance antifungal medication for life-threatening fungal infections (other than fluconazole <= 100 mg/day)
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
CompletedOne Study Center